
FUTURE PLANS AND USE OF [REDACTED]

FUTURE PLANS

Please see “Business—Our Strategies” for a detailed description of our future plans.

USE OF [REDACTED]

We estimate that we will receive net [REDACTED] from the [REDACTED] of approximately HK\$[REDACTED], after deducting [REDACTED] commissions, fees and estimated expenses payable by us in connection with the [REDACTED], assuming no [REDACTED] is exercised and assuming an [REDACTED] of HK\$[REDACTED] per Share, being the mid-point of the indicative [REDACTED] in this Document. Assuming an [REDACTED] at the mid-point of the indicative [REDACTED] range, we intend to use the net [REDACTED] we will receive from this [REDACTED] for the following purposes, subject to changes in light of our evolving business needs and changing market conditions:

- (i) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the payment of expenses for conducting further research and development activities, advancing clinical trials for more indications, and advancing selling and distribution activities of our Core Product, the System:
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the payment of expenses for the ongoing and future clinical trials and future commercialization efforts in China to expand the application of the System to new indications for the treatment of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorder, child development deficiency and other disorders. In particular, we plan to use our [REDACTED] as follows:
 - o approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for the following clinical trials and future commercialization efforts: (i) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for atrial fibrillation induced cognitive impairment, for which we completed patient enrollment of 200 patients in 2023 and data collection was completed in October 2024 and data analysis is expected to be completed by the second quarter of 2025. We expect to pay approximately HK\$[REDACTED] for research fees at cooperating hospitals (which are typically responsible for patient enrollment, management, in-trial medical check-ups, data collections and advising on medical science related issues), approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for test-related equipment, approximately HK\$[REDACTED] for technical support, approximately HK\$[REDACTED] for third party clinical services, approximately HK\$[REDACTED] for obtaining regulatory approval and approximately HK\$[REDACTED] for product promotion; (ii) approximately [REDACTED]% of the net [REDACTED], or approximately

FUTURE PLANS AND USE OF [REDACTED]

HK\$[REDACTED], is expected to be paid out for hypertension induced cognitive impairment, for which we completed patient enrollment of 200 patients in 2023 and data collection was completed in October 2024 and data analysis is expected to be completed by the second quarter of 2025. We expect to pay approximately HK\$[REDACTED] for research fees at cooperating hospitals (which are typically responsible for patient enrollment, management, in-trial medical check-ups, data collections and advising on medical science related issues), approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for clinical trial equipment, approximately HK\$[REDACTED] for technical support, approximately HK\$[REDACTED] for third party clinical services, approximately HK\$[REDACTED] for obtaining regulatory approval and approximately HK\$[REDACTED] for product promotion; (iii) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for coronary heart disease induced cognitive impairment, for which we completed patient enrollment of 200 patients in 2023 and data collection was completed in October 2024 and data analysis is expected to be completed by the second quarter of 2025. We expect to pay approximately HK\$[REDACTED] for research fees at cooperating hospitals (which are typically responsible for patient enrollment, management, in-trial medical check-ups, data collections and advising on medical science related issues), approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for clinical trial equipment, approximately HK\$[REDACTED] for technical support, approximately HK\$[REDACTED] for third party clinical services, approximately HK\$[REDACTED] for obtaining regulatory approval and approximately HK\$[REDACTED] for product promotion; (iv) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for amnesic mild cognitive impairment, for which we have completed patient enrollment in May 2023. We expect to complete data collection by the fourth quarter of 2024, and we plan to perform data cleaning and analysis in 2025. We expect to pay approximately HK\$[REDACTED] for research fees at cooperating hospitals (which are typically responsible for patient enrollment, management, in-trial medical check-ups, data collections and advising on medical science related issues), approximately HK\$[REDACTED] for test subject related fees and approximately HK\$[REDACTED] for obtaining regulatory approval; and (v) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to bone fracture induced pain. The trial has commenced and is expected to be completed by the fourth quarter of 2025. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees,

FUTURE PLANS AND USE OF [REDACTED]

approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees. See “Business—Our Product Pipeline—Core Product: Brain Function Information Management Platform Software System—Future Development Plans for Our System” for more details on ongoing clinical trials. Based on the clinical trial timeline described above, the following table sets forth a detailed breakdown of the amount we expect to incur for the abovementioned indications of the System.

	For the year ending December 31,	
	2025	2026
	<i>(HK\$ in millions)</i>	
Atrial fibrillation induced cognitive impairment	[REDACTED]	[REDACTED]
Hypertension induced cognitive impairment	[REDACTED]	[REDACTED]
Coronary heart disease induced cognitive impairment	[REDACTED]	[REDACTED]
Amnesic mild cognitive impairment	[REDACTED]	[REDACTED]
Bone fracture induced pain	[REDACTED]	[REDACTED]

- o approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the payment of expenses for conducting future clinical trials for other indications of the System.
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System for post-cardiac surgery rehabilitation, which is expected to enroll 200 subjects. The trial is expected to commence in the first quarter of 2025 and complete by the second half of 2026. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees, approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees.

FUTURE PLANS AND USE OF [REDACTED]

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to heart failure induced cognitive impairment, which is expected to enroll 200 subjects. The trial is expected to commence in the first half of 2026 and complete by the second half of 2028. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees, approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees.

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to anxiety. The trial is expected to commence in the first quarter of 2025 and complete by the second half of 2026. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees, approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees.

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to dyslexia, which is expected to enroll 400 subjects. The trial is expected to commence in the first quarter of 2025 and complete by the second half of 2026. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees, approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees.

FUTURE PLANS AND USE OF [REDACTED]

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to diabetes, which is expected to enroll 200 subjects. The trial is expected to commence in the first quarter of 2025 and complete by the second half of 2026. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees, approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees.
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the upgrade of the System’s utility as an integrated DTx for depression, which is expected to enroll 200 subjects. The trial is expected to commence in the first quarter of 2025 and complete by the second half of 2026. Trial expenses are expected to be broken down into approximately HK\$[REDACTED] for R&D and technical support, approximately HK\$[REDACTED] for researcher fees, approximately HK\$[REDACTED] for insurance, approximately HK\$[REDACTED] for testing and inspection fees, approximately HK\$[REDACTED] for test subject related fees, approximately HK\$[REDACTED] for data management and analysis, approximately HK\$[REDACTED] for third party clinical trial services and approximately HK\$[REDACTED] for ethics committee approval related fees.

FUTURE PLANS AND USE OF [REDACTED]

Based on the clinical trial timeline described above, the following table sets forth a detailed breakdown of the amount we expect to incur for the abovementioned indications of the System.

	For the year ending December 31,	
	2025	2026
	<i>(HK\$ in millions)</i>	
Post-cardiac surgery rehabilitation	[REDACTED]	[REDACTED]
Heart failure induced cognitive impairment	[REDACTED]	[REDACTED]
Anxiety	[REDACTED]	[REDACTED]
Dyslexia	[REDACTED]	[REDACTED]
Diabetes	[REDACTED]	[REDACTED]
Depression	[REDACTED]	[REDACTED]

Note:

* Represents amount for 2026 and beyond.

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the payment of expenses for further R&D of our System:
 - o approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the payment of expenses for preclinical research for new indications of the System; and
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be used for the application of the System to epilepsy. The project will involve conducting pre-tests in patients with epilepsy to assess whether the System design meets the needs of patients and to provide an initial assessment of efficacy and safety. The project has commenced in the first half of 2021. The clinical trial is expected to initiate in the second quarter of 2025 and data analysis is expected to be completed by the second quarter of 2026.
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to phenylketonuria induced cognitive impairment. The project will evaluate markers of cognitive

FUTURE PLANS AND USE OF [REDACTED]

impairment due to phenylketonuria and apply the pre-test data to support product development and improvement. The project has commenced in the first half of 2021. The clinical trial is expected to initiate in the first quarter of 2025, and data analysis is expected to be completed by the second half of 2026.

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to kidney disease induced cognitive impairment. The project will organize pre-tests to evaluate the efficacy and safety of the product and using the pre-test data to support product improvement. The project has commenced in the first half of 2021. The clinical trial is expected to be initiated in the first quarter of 2025 and data analysis is expected to be complete by the second half of 2026.
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to multiple sclerosis. The project will involve conducting assessments of cognitive impairment in patients with multiple sclerosis and organizing pre-tests to evaluate the efficacy and safety of the product. The project is expected to commence clinical trials in the first quarter of 2025 and complete by the second half of 2026.
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to hepatic encephalopathy. The project will organize pre-tests to investigate markers of cognitive impairment in patients with hepatic encephalopathy and develop cognitive assessment and intervention tools based on the data collected. The project is expected to commence clinical trials in the third quarter of 2025 and complete by the second half of 2026.
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to post-breast cancer surgery rehabilitation. The project will involve organizing pre-testing and preliminary evaluation of the efficacy and safety of the System in application to post-breast cancer surgery rehabilitation. The project has commenced in the first half of 2021. The clinical trial is expected to be initiated in the first quarter of 2025 and data analysis is expected to be completed by the first half of 2026.

FUTURE PLANS AND USE OF [REDACTED]

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to post-lung cancer surgery rehabilitation. The project will involve organizing pre-testing and preliminary evaluation of the efficacy and safety of the System in application to post-lung cancer surgery rehabilitation. The project has commenced in the first half of 2021. The clinical trial is expected to be initiated in the first quarter of 2025 and data analysis is expected to be completed by the first half of 2026.

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED] will be paid out for the application of the System to drug addiction. The project will involve organizing pre-testing and preliminary evaluation of the efficacy and safety of the System in application to drug-addiction. The project has commenced in the first half of 2021. The clinical trial is expected to be initiated in the first quarter of 2025 and data analysis is expected to be completed by the second half of 2026.

Based on the R&D timeline described above, the following table sets forth a detailed breakdown of the amount we expect to incur for the abovementioned indications of the System.

	For the year ending on December 31,	
	2025	2026
	<i>(HK\$ in millions)</i>	
Epilepsy	[REDACTED]	[REDACTED]
Phenylketonuria induced cognitive impairment	[REDACTED]	[REDACTED]
Kidney disease induced cognitive impairment	[REDACTED]	[REDACTED]
Multiple sclerosis	[REDACTED]	[REDACTED]
Hepatic encephalopathy	[REDACTED]	[REDACTED]
Post-breast cancer surgery rehabilitation	[REDACTED]	[REDACTED]
Post-lung cancer surgery rehabilitation	[REDACTED]	[REDACTED]
Drug addiction	[REDACTED]	[REDACTED]

FUTURE PLANS AND USE OF [REDACTED]

- o approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used to recruit additional R&D personnel with relevant academic and industry experience in brain sciences, DTx and other related fields for the further R&D of our System. Specifically, we intend to hire approximately 15, 19 and 20 employees in 2024, 2025 and 2026, respectively, for the further development of the System in terms of AI-related capabilities and product pipeline development capabilities. We intend to identify the R&D personnel to be hired through review of resume submissions and internal referrals that meet our requirements for the position, specifically:
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the recruitment of 15 algorithm engineers to develop large language models and other AI models for diagnostic and intervention applications in cognitive impairment.
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the recruitment of seven product managers/training task planners to design diagnostic and intervention products.
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the recruitment of eleven front-end developers to support the development of training tasks and the creation of front-end rendering and presentation for DTx products.
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the recruitment of 16 back-end developers to support back-end development of training tasks and implementation of back-end storage and front-end/back-end interaction for DTx products.
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for the recruitment of five Android development engineers to develop mobile interactive experiences for different application and training task formats.

FUTURE PLANS AND USE OF [REDACTED]

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for advancing selling and distribution activities of the System:
 - o approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for expanding our selling and distribution team to roll out marketing campaigns and other marketing efforts to promote the System; and
 - o approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for participating in more academic conferences and other industry events on cognitive impairment DTx to accelerate market acceptance of the System among hospitals and other customers.

See “Business—Sales and Marketing—Our Marketing Model” for details on our key marketing areas.

- (ii) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for helping establish new cognitive centers for more hospitals across China through which hospitals can use our products to diagnose and treat patients with cognitive impairment and/or other disorders. We plan to help to establish cognitive centers in at least 2,100 hospitals in China; specifically, we intend to renovate the involved premises and purchase the necessary equipment and multi-modal devices. We believe these cognitive centers are expected to enhance the market penetration of our products and boost our market share; We intend to seek cognitive center collaborations with medical institutions across China, focusing on provinces with large elderly populations such as Beijing, Sichuan, Guangdong, Henan and Shandong. In 2024, we plan to add more than one hundred new cognitive center collaborations. We intend to follow a three-phase penetration strategy. In the first phase, we intend to focus on top medical institutions with advanced clinical experience in relevant therapeutic areas, such as Xuanwu Hospital for neurodegenerative diseases and Anzhen Hospital for cardiovascular diseases. The goal is to establish a base of model cognitive center collaborations as a foundation for further expansion. In the second stage, we intend to reach out to large general hospitals and specialized hospitals in various cities. We intend to prioritize provinces with a large population and a high proportion of elderly people. In the third stage, we intend to rely on the experience of cognitive center cooperation with top hospitals to widely promote the cognitive center cooperation model in second- and third-tier cities.

FUTURE PLANS AND USE OF [REDACTED]

- (iii) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for strengthening our capabilities in AI and related technologies:
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for (i) strengthening our virtual human technology; and (ii) building and/or improving various models under our AI technology, such as a multimodal cognitive computing model to enable more accurate assessment and diagnosis, a causal-based adaptive collaborative intervention model to make the System offer more personalized and self-adaptive trainings that lead to enhancement of patient cognitive functions, a multimodal affective computing model and a large language model to better understand and interpret patient input during assessment. The multimodal cognitive computing model is a model that uses various types of data, including a patient's speech, gait, expression, eye movement, and other data, to create a recognition model. By integrating different modalities of information, this model can efficiently and accurately analyze large amounts of multimodal data input. It helps in the analysis of cognitive impairments and improves diagnostic capabilities. The causal-based adaptive collaborative intervention model is a model based on causal inference that aims to provide optimal recommendations on the combination of interventions for patients; and
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for recruiting personnel to strengthen our capabilities in AI and related technologies.
- (iv) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for accelerating the research, development and commercialization of other product candidates in and beyond our current product pipeline:
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for conducting and completing ongoing preclinical and clinical development of our current products and product candidates other than the System; and

FUTURE PLANS AND USE OF [REDACTED]

- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be paid out for developing DTx products to cover new types of cognitive impairments and beyond. We plan to commence the commercialization of BCAT in the second half of 2024, SAS in the second half of 2024 and DSS in the second half of 2024. We also plan to commence the commercialization of the Cognitive Impairment Treatment Software in the EU in April 2025. For example, we plan to develop DTx products that focus on cognitive impairments as well as neurological and psychiatric symptoms (such as signs of depression, anxiety and Symptoms of post-traumatic stress disorder (the “PTSD”)) arising out of orthopedics and endocrine related injuries and/or diseases. In addition, we also intend to develop DTx products to help manage the rehabilitation plan design and daily execution for bone fracture and other orthopedic patients; and
- (v) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for brain science and DTx research centers in collaboration with academic institutions and hospitals:
- approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for supporting the operational activities of R&D projects at these research centers, including expenses to enable the execution of various stages of preclinical and clinical trials such as patient enrollment, trial administration, data collection and analysis, among other activities;
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for obtaining the necessary licenses, equipment and other infrastructure to initiate the operations of the research centers and the R&D projects; and
 - approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for recruiting R&D personnel to work for the research centers.
- (vi) approximately [REDACTED]% of the net [REDACTED], or approximately HK\$[REDACTED], is expected to be used for our working capital and other general corporate purposes.

If the [REDACTED] is set at HK\$[REDACTED] per Share, being the low end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will decrease to approximately HK\$[REDACTED]. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the high end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will increase to approximately HK\$[REDACTED]. The above allocation of the net [REDACTED] will be adjusted on a pro rata basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the indicative [REDACTED] stated in this Document.

FUTURE PLANS AND USE OF [REDACTED]

If the [REDACTED] is exercised in full, the net [REDACTED] that we will receive will be approximately HK\$[REDACTED], assuming an [REDACTED] of HK\$[REDACTED] per Share (being the mid-point of the indicative [REDACTED] range). If the [REDACTED] is set at HK\$[REDACTED] per Share, being the low end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will decrease to approximately HK\$[REDACTED]. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the high end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will increase to approximately HK\$[REDACTED]. In the event that the [REDACTED] is exercised in full, we intend to apply the additional net [REDACTED] to the above purpose in the proportions stated above.

To the extent that our net [REDACTED] are not sufficient to fund the purposes set out above, we intend to fund the balance through a variety of means, including cash generated from operations, bank loans and other borrowings. To the extent that the net [REDACTED] from the [REDACTED] are not immediately used for the purposes described above and to the extent permitted by the relevant laws and regulations, they will be placed in short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions). We will issue an appropriate announcement if there is any material change to the above proposed use of [REDACTED].